Market Place
Sourcing Support
Genoskin Unveils Hyposkin Ex Vivo Platform At SOT Conference
19 Mar 2026 //
PHARMIWEB
Unnatural Products Raises $45M Series B for Macrocyclic Peptides
16 Mar 2026 //
GLOBENEWSWIRE
Argenx Unveils Transformative MG, CIDP Data at 2026 AAN
06 Mar 2026 //
GLOBENEWSWIRE
Argenx`s Vyvgart Posts Ph. 3 Win In Ocular Myasthenia Gravis
26 Feb 2026 //
FIERCE PHARMA
Argenx`s VYVGART In ACHR-Ab Seronegative GMG Gets FDA Priority
13 Jan 2026 //
GLOBENEWSWIRE
Argenx lays out details on Vyvgart`s seronegative gMG win
30 Oct 2025 //
FIERCE PHARMA
Argenx Showcases Immunology Innovation At 2025 AANEM Meeting
15 Oct 2025 //
GLOBENEWSWIRE
Fujifilm, Argenx Shift Vyvgart Production to US
18 Sep 2025 //
FIERCE PHARMA
Argenx Pursues Vyvgart Nod in Seronegative Myasthenia Gravis
26 Aug 2025 //
GLOBENEWSWIRE
Argenx Makes $1.5B+ Play for UNP’s Macrocyclic Peptides
02 Jul 2025 //
BIOSPACE
Argenx Ph2 Efgartigimod Data Positive in Myositis, Sjogren`s
10 Jun 2025 //
GLOBENEWSWIRE
Argenx brews up ad for Vyvgart Hytrulo prefilled syringe in gMG
08 May 2025 //
FIERCE PHARMA
argenx to Present at Upcoming Investor Conferences
26 Nov 2024 //
GLOBENEWSWIRE
Argenx Advance Efgartigimod SC in Idiopathic Inflammatory Myopathy
20 Nov 2024 //
GLOBENEWSWIRE
Argenx & Zai Lab Announce Vyvgart Approval for CIDP in China
11 Nov 2024 //
GLOBENEWSWIRE
Argenx Drops Post-Covid Program, Mirum Picks Bile Duct Disease Dose
17 Jun 2024 //
ENDPTS
iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar
10 May 2024 //
ENDPTS
argenx Advances Clinical Development of Efgartigimod in Sjogren`s Disease
27 Mar 2024 //
GLOBENEWSWIRE
FUJIFILM Diosynth Expands Manufacturing Agreement with Argenx for Efgartigimod
25 Mar 2024 //
PRESS RELEASE
argenx Announces FDA Acceptance of sBLA with Priority Review for VYVGART
20 Feb 2024 //
GLOBENEWSWIRE
argenx Highlights 2024 Strategic Priorities
08 Jan 2024 //
GLOBENEWSWIRE
argenx Reports Topline Results from ADDRESS Study of Efgartigimod in Pemphigus
19 Dec 2023 //
GLOBENEWSWIRE
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod
15 Sep 2023 //
GLOBENEWSWIRE
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart
20 Jun 2023 //
GLOBENEWSWIRE
Proof-of-concept efgartigimod trial for AAV expected this year
08 May 2023 //
PRESS RELEASE
Tiny multiomics biotech secures former J&J drug, new execs and new financing
28 Mar 2023 //
ENDPTS
FDA extends review of argenx`s subcutaneous efgartigimod
01 Feb 2023 //
FIERCE PHARMA
Argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
27 Jan 2023 //
GLOBENEWSWIRE
